摘要
目的:探讨阿法骨化醇联合阿伦膦酸钠(ALN)治疗绝经后骨质疏松症(PMO)患者的临床效果及对其疼痛症状和骨代谢指标的影响。方法:选取2015年2月-2017年3月本院门诊收治的80例PMO患者,根据随机数字表法将80例PMO患者分为对照组(n=40)和观察组(n=40)。对照组予以常规钙剂+阿法骨化醇治疗,观察组在对照组基础上联合ALN治疗。连续治疗12个月后观察比较两组治疗总有效率、治疗前后疼痛症状、相关骨代谢指标及不良反应发生率。结果:观察组治疗总有效率(95.00%)较对照组(80.00%)高(P<0.05);两组治疗后翻身、前屈后伸及自发性腰背痛VAS评分均较治疗前降低,且观察组降低更明显(P<0.05);两组治疗后血清骨钙素(BGP)、骨碱性磷酸酶(BALP)、Ⅰ型胶原C端肽(CTX)及抗酒石酸酸性磷酸酶5b(TRACP-5b)水平均较治疗前降低,且观察组降低更明显(P<0.05);两组治疗期间不良反应发生率对比,差异无统计学意义(P>0.05)。结论:阿法骨化醇联合ALN治疗PMO临床效果显著,可缓解疼痛不适,改善骨质疏松症状且安全可靠。
Objective:To investigate the clinical efficacy of Alfacalcidol combined with ALN in the treatment of PMO patients and its effects on pain symptoms and bone metabolism indexes.Method:A total of 80 patients with PMO admitted to our hospital from February 2015 to March 2017 were selected.Eighty patients with PMO were divided into the control group(n=40)and the the observation group(n=40)according to random number table method.The patients in the control group were treated with conventional calcium+Alfacalcidol,and the patients in the observation group were combined with ALN treatment on the treatment of the control group.After 12 months of continuous treatment,the total effective rate of treatment,pain symptoms before and after treatment,related bone metabolic markers and the incidence of total adverse reactions of two groups were observed.Result:The total effective rate of treatment in the observation group(95.00%)was higher than that in the control group(80.00%)(P<0.05).The VAS scores of two groups after treatment were significantly lower than those of before treatment,and the observation group were more obvious(P<0.05).The levels of BGP,BALP,CTX and TRACP-5b in the two groups were lower than those before treatment,and the observation group were more obvious(P<0.05).There was no significant difference in the incidence of total adverse reactions between two groups(P>0.05).Conclusion:Alfacalcidol combined with ALN in the treatment of PMO patients has significant clinical effects,can relieve pain and discomfort,improve osteoporosis symptoms and it is safe and reliable.
作者
陆锐均
钟伟斌
LU Ruijun;ZHONG Weibin(The Fifth Affiliated Hospital of Guangzhou Medical University,Guangzhou 510700,China;不详)
出处
《中国医学创新》
CAS
2020年第10期15-18,共4页
Medical Innovation of China
